Dr. Terri Lynn Parker, MD

Dr. Parker practices at Yale New Haven Psychiatric Hospital (York St) in New Haven, Connecticut.

Dr. Parker's NPI, 1285825232, was assigned on August 6, 2007. Dr. Parker holds Connecticut license 46863.

Dr. Parker's primary practice is Yale New Haven Psychiatric Hospital (York St), at 20 York Street, New Haven, CT 06510. The practice phone is (203) 688-5900.

Dr. Parker's primary practice is Yale New Haven Psychiatric Hospital (York St) in New Haven, Connecticut. Dr. Parker is also affiliated with Yale New Haven Hospital. The medical group on file is Yale Health. Dmand AI also links Dr. Parker to 2 more hospitals, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Parker practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Parker's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Parker is licensed in Connecticut.

CMS data shows 454 Medicare services from Dr. Parker across 6 procedure codes in 2024, for 182 Medicare patients. Medicare paid $31,215 for them.

CMS counts 182 Medicare patients who saw Dr. Parker in 2024. The largest group is 65 to 74, with 78 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 15% are also on Medicaid. Their average risk score is 2.54, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Parker's median patient age at 73, with 57% women.

In 2024, Dr. Parker wrote 359 Medicare Part D claims for 69 patients. 47% of them were for generic drugs. CMS names the drug for 296 of them, across 8 drugs with 11 or more claims each, at $3,201,289 in total drug cost. In 2023, CMS named 236 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Parker for performance year 2024, reported as part of a group. Dr. Parker accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Parker as offering telehealth.

Dmand AI links 32 papers to Dr. Parker, published from 2010 to 2025. 2018 was the busiest year, with 4. The most frequent topics are Multiple Myeloma, Antineoplastic Combined Chemotherapy Protocols and Dexamethasone. Dr. Parker has published most often in Clin Lymphoma Myeloma Leuk. Dr. Parker's most frequent co-authors are Noffar Bar, MD, Natalia Neparidze, MD and Ajay K. Nooka, MD.

Dmand AI links Dr. Parker to 5 clinical trials, 2 of them phase 1/2 studies. 2 are still active or recruiting. Conditions studied include Multiple Myeloma, Blood Protein Disorders and Macroglossia. SWOG Cancer Research Network sponsors the most, 2.

CMS Open Payments shows 18 general payments to Dr. Parker from 7 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 100% of the total. Janssen Pharmaceuticals, Inc paid the most, $335.